Macrolide Drug Class List

Drugs in Drug Class: Macrolide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ZITHROMAX	azithromycin	INJECTABLE;INJECTION	050733-001	Jan 30, 1997	AP	RX	Yes	Yes
Pfizer	ZITHROMAX	azithromycin	TABLET;ORAL	050711-001	Jul 18, 1996	AB	RX	Yes	No
Pfizer	ZITHROMAX	azithromycin	TABLET;ORAL	050784-001	May 24, 2002	AB	RX	Yes	No
Pfizer	ZITHROMAX	azithromycin	FOR SUSPENSION;ORAL	050710-001	Oct 19, 1995	AB	RX	Yes	No
Pfizer	ZITHROMAX	azithromycin	FOR SUSPENSION;ORAL	050710-002	Oct 19, 1995	AB	RX	Yes	Yes
Apotex	FIDAXOMICIN	fidaxomicin	TABLET;ORAL	219559-001	Feb 2, 2026	AB	RX	No	No
Actavis Labs Fl	FIDAXOMICIN	fidaxomicin	TABLET;ORAL	208443-001	Jan 16, 2024	AB	RX	No	No

Macrolide Drug Market Dynamics and Patent Landscape: Exclusivity Timelines, Orange Book Status, Patent-Expiry Risk, and Generic/Biosimilar Entry Barriers

Last updated: July 6, 2026

The macrolide class spans widely used small-molecule antibiotics with recurring sales cycles driven by guideline positioning, resistance patterns, payer mix, and pediatric/renal safety demand. Patent exposure is mostly mediated by (1) staggered expiries of active-ingredient and salt/polymorph families, (2) formulation and method-of-use patents (especially pediatric and extended-release), and (3) label-protection via FDA Supplements and Orange Book–listed exclusivities. For most marketed macrolides, the competitive pressure is dominated by generic penetration rather than biosimilars (biosimilars apply to biologics, not antibiotics). The highest forward risk typically sits in late-life formulation patents and any remaining brand “new indication” or “new formulation” exclusivities.

What patents protect macrolide antibiotics, and where do patent estates cluster?

Macrolide portfolios protect three layers of IP: the core molecule (active ingredient), commercial dosage forms (formulations), and clinical use scope (method-of-use/label). Across the class, the patent estate typically clusters in these buckets:

Core active-ingredient families: what they tend to cover

Featured at the top of the chain for first-in-class launches:

• chemical composition-of-matter patents on the macrolide scaffold
• salt and hydrate forms, including polymorph claims
• manufacturing intermediates and process patents

Formulation families: what they tend to cover

Commonly pursued once active-ingredient claims age out:

• taste-masking and granulation approaches (important for pediatric suspensions)
• improved bioavailability or reduced variability
• extended-release matrices and controlled delivery
• high-concentration suspensions and reconstitution improvements
• dissolution-control patents for tablets/capsules

Method-of-use and label-protection patents: what they tend to cover

Used to keep brand exclusivity tied to specific clinical positioning:

• dosing regimens by indication (where permitted by the claim)
• resistant organism targeting or pathogen coverage language tied to label updates
• safety-related dosing in special populations (when the claim is enforceable)

When does macrolide exclusivity expire, and how do you forecast generic entry timing?

Macrolides show a mix of three timing regimes:

1. statutory patent expiry of composition and manufacturing/process patents
2. FDA Hatch-Waxman “Orange Book” listed patent expiry
3. marketing exclusivity periods linked to NDAs and certain regulatory exclusivities (not biosimilar-related)

Typical exclusivity sequencing for macrolides

For brand NDAs that list multiple Orange Book patents, generic entry risk is driven by the first effective date when a generic can carve around invalid/expired patents, including:

• Paragraph IV challenges to Orange Book patents
• section viii “carve-in” or “carve-out” label strategies (when permitted)
• tentative approval timing after successful ANDA submission and litigation outcomes

Practical forecast framework for macrolides

• Identify the earliest Orange Book patent expiry among listed patents for the listed dosage form/strength.
• Map secondary patents (formulation and method-of-use) to see whether they extend exclusivity beyond the core molecule.
• Track any litigation settlements that create a delayed launch “stay” or licensed entry date.
• Overlay FDA approval pathway timing (ANDAs typically proceed to approval after a period contingent on legal status).

What is the Orange Book status of key macrolide brands, and which listed patents matter most?

Orange Book status is the control point for Hatch-Waxman. For macrolides, practical “patents that matter” are usually:

• the listed composition-of-matter patent (if still unexpired)
• formulation patents tied to the specific dosage form (capsule/tablet/suspension/ER)
• dosing regimen patents if they are listed and enforceable (less common than formulation protection)
• manufacturing process patents if they are listed for the drug product

Dosage-form-specific exposure patterns

• Oral suspensions: higher formulation patent activity, often centered on taste masking and particle size distribution.
• Extended-release tablets/capsules: longer-lived formulation estates are more common.
• Tablets/capsules: core composition patents dominate early, then formulation patents predominate.

How strong is the patent estate for macrolides in the U.S., and what claim types drive litigation outcomes?

Macrolide estates can be fragmented across multiple assignees and continuation filings. Litigation strength typically hinges on:

• whether claims are close to the drug product’s functional properties (bioavailability, release profile, dissolution)
• whether claims are broad enough to cover generic manufacturing choices without literal infringement
• whether enforceable patents are tied to the approved formulation rather than peripheral processes

Claim types most often asserted (class-wide patterns)

• composition-of-matter and salt/polymorph claims early in the lifecycle
• formulation claims later, especially those describing:
  • matrix composition and release kinetics
  • granulation particle size and dissolution behavior
  • excipient systems linked to specific performance targets

Claim types that frequently face entry barriers

• patents that require specific ratios, particle size distributions, or dissolution curves
• patents that are difficult to design around because they are tied to product performance

Which companies challenge macrolide patents via Paragraph IV, and what generic entry risks exist?

Paragraph IV challenges concentrate among large generic and specialty players with established ANDA pipelines. For macrolides, risk is typically:

• rapid entry once the first actionable Orange Book patent is found invalid/expired
• delayed entry when settlements specify a later “launch date” or continued brand supply agreements

Generic entry risk drivers

• count of Orange Book patents that remain unexpired at the time of ANDA approval
• whether the ANDA is approved with a “skinny label” that avoids method-of-use claim coverage
• complexity of formulation design-around for taste-masking or extended-release performance

What is the market dynamic for macrolides, and how does patent status affect pricing and share?

Macrolides sit in competitive antibiotic markets where price declines follow generic entry and payer behavior is sensitive to:

• acquisition cost and formulary positioning
• clinical outcomes and tolerability (especially pediatric acceptability)
• resistance patterns and guideline shifts

Post-generic pricing behavior

• after first authorized generic or full generic entry, macrolide unit prices typically fall quickly, but reimbursement and contracting determine net price and volume capture
• brand retention is often driven by:
  • superior formulation acceptance (pediatric suspension palatability)
  • contracting or inventory management
  • residual exclusivity pockets tied to specific strengths/dosage forms

Revenue exposure concentrated by dosage form

Patent-driven share retention tends to be strongest where:

• the branded product is differentiated by formulation performance
• the generic must meet stringent bioavailability/bioperformance specs tied to the claimed formulation

How do specific macrolides compare on patent exposure and competitive intensity?

The macrolide class is not monolithic. Exposure differs by generation, launch era, and whether later-life formulation upgrades created additional IP layers.

Clarithromycin: where the competitive pressure typically concentrates

• broad generic availability in the U.S.
• residual brand presence usually tied to specific dosage forms, formulations, or label refinements where still protected

Azithromycin: supply and formulation-driven competition

• generics have deep presence, with competitive behavior influenced by:
  • pediatric suspension performance demands
  • contracting dynamics and procurement
• remaining risk pockets typically come from late-life formulation patents and any label protection still in force

Erythromycin: often older and heavily generic

• extensive generic coverage
• formulation IP is still relevant where taste-masking or specific release profiles are protected (less frequently the center of new litigation compared with more recently protected products)

Newer macrolides (where applicable): higher odds of later-life estates

• later launches and life-cycle management can produce longer staggered expiries via:
  • formulation and process patents
  • new indication/labeled dosing updates packaged with regulatory exclusivity

Which macrolide patents cover formulations, and what design-around barriers exist for generic ANDAs?

Formulation patents represent the highest design-around friction in macrolides. Common design-around vectors:

• change excipient system while maintaining dissolution profile
• change granulation method and particle size distribution
• reformulate to match performance specs without using claimed composition ratios
• for ER products: adjust matrix composition and release mechanism to fall outside claim limits

What to look for when assessing infringement risk in formulation patents

• whether claims are product-by-process tied to how the drug product is made
• whether claims are functional with measurable performance criteria (dissolution, bioavailability)
• whether claims specify manufacturing steps, temperatures, milling or granulation parameters that are hard to reproduce verbatim

Do macrolides face biosimilar risk, and how does exclusivity differ from biologics?

Macrolides are small-molecule antibiotics. Biosimilar frameworks do not apply. Exclusivity is handled through:

• Hatch-Waxman patent listing and ANDA litigation
• regulatory data exclusivity and marketing exclusivity applicable to NDAs (not biosimilarity)

What macrolide patent litigation affects generic launch dates, and how do settlements usually work?

Macrolide litigation affects launch dates through:

• automatic statutory stays after Paragraph IV filing
• court decisions on infringement and validity
• settlement agreements that define “effective launch” dates or licensing schedules

Settlement patterns that matter for forecasting

• delayed generic launch date that may align with:
  • expiry of a key formulation patent
  • expiration of a last-to-expire Orange Book patent
• carve-outs that allow partial label entry while avoiding protected indications/dosing (where method-of-use claims drive outcomes)

What FDA regulatory pathway and Orange Book listing mechanics drive macrolide exclusivity?

Macrolide brands are typically NDAs with listed patents. Generic entry hinges on:

• ANDA eligibility for same active ingredient and labeled indication scope
• paragraph IV certifications against Orange Book patents
• timing of tentative approvals and final approvals after litigation

How “listed patents” map to real launch risk

• If a formulation patent is listed only for certain strengths or dosage forms, generics may launch other strengths earlier (risk compartmentalization).
• If a method-of-use patent is tied to a specific indication, label strategy and skinny label approvals become central.

Where are the highest remaining patent/IP barriers across the macrolide class?

Across the class, remaining barriers generally reside in:

• late-life formulation upgrades that received new patent listings
• ER or pediatric-optimized products where formulation differentiation is central
• any still-active composition patents on newer macrolides or newer dosage forms/strengths

What tends to be “low barrier”

• fully generic, long-commercialized tablets/capsules where core chemistry patents are expired and no meaningful formulation patents remain listed
• products where Orange Book listings are sparse or only include patents that are already challenged/expired

Key Takeaways

• Macrolide patent exposure is mostly about small-molecule Orange Book-listed patents, not biosimilars.
• Generic entry timing is driven by the first effective unexpired Orange Book patent and whether litigation or settlements delay approval.
• Formulation patents, especially for pediatric suspensions and extended-release, are the main design-around and infringement barrier late in the lifecycle.
• The biggest market dynamic is price and formulary share after generic launches, with brand retention concentrated in differentiated formulations and any remaining label-protection pockets.

FAQs

1) How do you identify which macrolide Orange Book patents are most likely to be asserted in litigation?
Focus on the listed patents that cover the approved drug product’s specific dosage form and performance-defining formulation attributes, not peripheral process patents.

2) What generic launch scenario is most common after the first macrolide Paragraph IV win?
Launch after tentative approval becomes effective, but only for the strength/dosage form unblocked by remaining unexpired formulation patents.

3) Do macrolide “skinny label” strategies reduce litigation risk, and when do they work?
Yes when the remaining asserted patents are indication- or dosing-regimen linked and the ANDA carves out the protected label scope permitted by the statute and FDA labeling.

4) Which macrolide product attributes most often lead to formulation patent coverage?
Taste masking, dissolution control, bioavailability consistency, and extended-release release kinetics for oral dosage forms.

5) How does pediatric dosing and suspension acceptability change macrolide IP strategy?
It drives life-cycle management through formulation and performance patents tied to pediatric-friendly suspensions and reconstitution or palatability improvements.

---

References (APA)

No sources were provided in the prompt, and no external Orange Book or litigation databases were cited.